BR112022024728A2 - Compostos e métodos para tratamento de distúrbios oftalmológicos - Google Patents

Compostos e métodos para tratamento de distúrbios oftalmológicos

Info

Publication number
BR112022024728A2
BR112022024728A2 BR112022024728A BR112022024728A BR112022024728A2 BR 112022024728 A2 BR112022024728 A2 BR 112022024728A2 BR 112022024728 A BR112022024728 A BR 112022024728A BR 112022024728 A BR112022024728 A BR 112022024728A BR 112022024728 A2 BR112022024728 A2 BR 112022024728A2
Authority
BR
Brazil
Prior art keywords
methods
compounds
treatment
ophthalmological
reducing
Prior art date
Application number
BR112022024728A
Other languages
English (en)
Inventor
Kelly Darren
Papadimitriou Michelle
Burns Chris
Daniels Eric
Original Assignee
Occurx Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901856A external-priority patent/AU2020901856A0/en
Application filed by Occurx Pty Ltd filed Critical Occurx Pty Ltd
Publication of BR112022024728A2 publication Critical patent/BR112022024728A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSTOS E MÉTODOS PARA TRATAMENTO DE DISTÚRBIOS OFTALMOLÓGICOS. São divulgados aqui métodos de administração de ácido (E)-2-[[3-metóxi-4-(difluorometóxi)fenil-1-oxo-2-propenil]amino]benzoico a um indivíduo, que envolvem regimes de administração particulares para a prevenção, tratamento, redução da gravidade e/ou redução da probabilidade de recorrência de condições oftalmológicas tais como retinopatia diabética e vitreorretinopatia proliferativa. Estas condições oftalmológicas podem ter consequências graves, incluindo a perda da visão e, em alguns casos, cegueira.
BR112022024728A 2020-06-05 2021-06-03 Compostos e métodos para tratamento de distúrbios oftalmológicos BR112022024728A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901856A AU2020901856A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
AU2020901858A AU2020901858A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
PCT/US2021/035749 WO2021247900A1 (en) 2020-06-05 2021-06-03 Compounds and methods for the treatment of eye disorders

Publications (1)

Publication Number Publication Date
BR112022024728A2 true BR112022024728A2 (pt) 2023-03-07

Family

ID=78829970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024728A BR112022024728A2 (pt) 2020-06-05 2021-06-03 Compostos e métodos para tratamento de distúrbios oftalmológicos

Country Status (11)

Country Link
US (1) US20230270703A1 (pt)
EP (1) EP4161527A4 (pt)
JP (1) JP2023529845A (pt)
KR (1) KR20230024331A (pt)
CN (1) CN116033901A (pt)
AU (1) AU2021284380A1 (pt)
BR (1) BR112022024728A2 (pt)
CA (1) CA3185849A1 (pt)
IL (1) IL298733A (pt)
MX (1) MX2022015327A (pt)
WO (2) WO2021247900A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4308541A1 (en) * 2021-03-17 2024-01-24 OccuRx Pty Ltd Compounds for the treatment of disorders and salts and polymorphs thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1008347A4 (en) * 1997-04-18 2002-02-06 Kissei Pharmaceutical REMEDIES FOR PROPHYLAXIS OR TREATMENT OF DISEASES RESULTING IN EXCESSIVE PROLIFERATION OF PIGMENTAL RETINE EPITHELIAL CELLS
CN1602207A (zh) * 2001-12-11 2005-03-30 法布罗根股份有限公司 抑制眼病理过程的方法
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CA2702984C (en) * 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
JP2011006406A (ja) * 2009-05-29 2011-01-13 Santen Pharmaceut Co Ltd トラニラストを含有する網膜疾患の予防または治療剤
TR201904760T4 (tr) * 2010-11-24 2019-04-22 Occurx Pty Ltd İnflamasyon ve vasküler proliferasyon ile ilişkili göz hastalıklarının tedavi edilmesine yönelik yöntemler.
US10780070B2 (en) * 2013-10-18 2020-09-22 The Schepens Eye Research Institute, Inc. Alpha-aminoadipate for treatment of vision loss and restoring sight

Also Published As

Publication number Publication date
KR20230024331A (ko) 2023-02-20
MX2022015327A (es) 2023-02-22
IL298733A (en) 2023-02-01
WO2021247901A1 (en) 2021-12-09
CA3185849A1 (en) 2021-12-09
WO2021247900A1 (en) 2021-12-09
EP4161527A4 (en) 2024-06-26
CN116033901A (zh) 2023-04-28
JP2023529845A (ja) 2023-07-12
US20230270703A1 (en) 2023-08-31
EP4161527A1 (en) 2023-04-12
AU2021284380A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
Li et al. A prospective study of Gasserian ganglion pulsed radiofrequency combined with continuous radiofrequency for the treatment of trigeminal neuralgia
Weiss et al. Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION)
Lönngren et al. The growth factor response in ischemic rat retina and superior colliculus after brimonidine pre-treatment
CA2970315C (en) Use of anti-vegf agents to treat lesions in macular degeneration patients
Antoun et al. Rate of corneal collagen crosslinking redo in private practice: risk factors and safety
WO2018191450A3 (en) GENE THERAPY FOR A DEFICIENCY IN AADC
BR112022024728A2 (pt) Compostos e métodos para tratamento de distúrbios oftalmológicos
Gaster et al. Corneal collagen cross-linking for keratoconus and post-LASIK ectasia
Chan et al. Combined application of prophylactic corneal cross‐linking and laser in‐situ keratomileusis–a review of literature
Del Rosso et al. Topical oxymetazoline hydrochloride cream 1% for the treatment of persistent facial erythema of rosacea in adults: a comprehensive review of current evidence
Paciuc-Beja et al. Oculocardiac reflex during intravitreal injection
Beckman Epithelium-on corneal collagen cross-linking with hypotonic riboflavin solution in progressive keratoconus
Xu et al. Pregabalin mediates retinal ganglion cell survival from retinal Ischemia/Reperfusion Injury Via the Akt/GSK3β/β-Catenin signaling pathway
BR112017025189A2 (pt) composição e usos da mesma
Sugano et al. Botulinum toxin for strabismus correction
Malec-Milewska et al. 5% lidocaine medicated plasters vs. sympathetic nerve blocks as a part of multimodal treatment strategy for the management of postherpetic neuralgia: A retrospective, consecutive, case-series study
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
Elsawy Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema
Horovitz et al. Crosslinking: an updated and effective insight
Piri et al. Photodynamic therapy and intravitreal bevacizumab with versus without triamcinolone for neovascular age-related macular degeneration; a randomized clinical trial
Hurley et al. Examining the efficacy of verteporfin photo-dynamic therapy (PDT) at different dose & fluence levels
TW202421653A (zh) 用TACI-Fc融合蛋白治療膜性腎病的方法
Watson et al. Intratympanic pharmacology for dizzy patients
Pangal et al. Evaluation of Photodynamic Therapy-Combined Intravitreal Bevacizumab in Age Related Macular Degeneration
Lim et al. 4 Advances in Corneal Crosslinking